Physician profile
Ann E Wood
NPI 1992034284
$6,921.26
in general payments reported to CMS, 2019-2025
56 companies · $1,537 in 2025
The $1,537 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $185 · 2022: $1,786 · 2023: $1,759 · 2024: $1,654 · 2025: $1,537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,731 · Education: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,731.15 |
| Education | $219.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $631.64 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $603.80 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $599.37 | 2022-2025 | Tagrisso, Imfinzi, Enhertu |
| Seagen INC. | $558.48 | 2021-2023 | Tukysa, Adcetris, Padcev |
| Gilead Sciences, INC. | $337.06 | 2021-2025 | Trodelvy |
| Janssen Biotech, INC. | $304.48 | 2022-2025 | Rybrevant, Carvykti, Talvey |
| Takeda Pharmaceuticals U.S.A., INC. | $244.10 | 2022-2025 | Ninlaro, Iclusig, Fruzaqla |
| Pfizer INC. | $242.23 | 2021-2025 | |
| Astellas Pharma US INC | $211.63 | 2023-2025 | Xtandi, Vyloy |
| E.R. Squibb & Sons, L.L.C. | $173.68 | 2022-2025 | Opdivo, Reblozyl |
| Incyte Corporation | $169.85 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Genzyme Corporation | $166.81 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $163.49 | 2022-2025 | Libtayo |
| Celgene Corporation | $151.33 | 2022-2025 | Reblozyl |
| Abbvie INC. | $150.49 | 2024-2025 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $136.56 | 2022-2024 | Jaypirca, Verzenio, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $121.55 | 2022-2023 | Imbruvica |
| Puma Biotechnology, INC. | $110.29 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $109.07 | 2022-2025 | Ultomiris, Soliris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.16 | 2022-2025 | Gilotrif |
| Exelixis INC. | $99.35 | 2022-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $96.11 | 2022-2023 | |
| Pharmacosmos Therapeutics INC. | $88.85 | 2022-2023 | Monoferric |
| Array Biopharma INC | $81.28 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Blueprint Medicines Corporation | $76.40 | 2022-2024 | Ayvakit |
| Kite Pharma, INC. | $72.43 | 2022-2025 | Yescarta |
| Amgen INC. | $71.62 | 2022-2023 | Kyprolis, Blincyto |
| Mirati Therapeutics, INC. | $66.94 | 2023 | Krazati |
| Beigene USA, INC. | $65.04 | 2022-2025 | Brukinsa, Tevimbra |
| Adc Therapeutics America, INC. | $61.32 | 2022-2025 | |
| Beone Medicines USA, INC. | $61.21 | 2025 | Tevimbra, Brukinsa |
| Genentech USA, INC. | $59.88 | 2023-2024 | Venclexta, Columvi, Polivy |
| Stemline Therapeutics INC. | $57.60 | 2024-2025 | Orserdu |
| Deciphera Pharmaceuticals INC. | $51.36 | 2022-2025 | Romvimza, Qinlock |
| Immunogen, INC. | $50.28 | 2023 | Elahere |
| Eisai INC. | $47.98 | 2022-2023 | |
| Coherus Oncology, INC. | $45.12 | 2022-2023 | |
| Tersera Therapeutics LLC | $41.86 | 2022-2023 | Zoladex |
| Glaxosmithkline, LLC. | $40.87 | 2022-2025 | Jemperli, Zejula |
| Sumitomo Pharma America, INC. | $35.92 | 2023 | Orgovyx |
| Rigel Pharmaceuticals, INC. | $35.23 | 2023-2024 | Tavalisse, Rezlidhia |
| Daiichi Sankyo INC. | $35.16 | 2021-2022 | |
| Emd Serono, INC. | $33.62 | 2022-2025 | |
| Recordati_rare_diseases_inc. | $26.52 | 2025 | Enjaymo |
| Aveo Pharmaceuticals, INC. | $26.05 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $23.79 | 2022 | |
| Pharmaessentia USA Corporation | $23.29 | 2025 | Besremi |
| Acrotech Biopharma INC. | $23.00 | 2022 | |
| Jazz Pharmaceuticals INC. | $19.40 | 2022 | |
| Genmab U.S., INC. | $17.97 | 2025 | Epkinly |
| Morphosys, US INC. | $17.45 | 2022 | |
| Karyopharm Therapeutics INC. | $17.36 | 2023 | Xpovio |
| Servier Pharmaceuticals LLC | $17.29 | 2025 | |
| Myovant Sciences INC. | $16.26 | 2022 | |
| Sobi, INC | $16.13 | 2025 | |
| Global Blood Therapeutics, INC. | $15.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.